Amgen on Tuesday said its experimental weight loss injection helped patients with obesity lose up to 20% of their weight on average after a year in a critical mid-stage trial, as the company races to join the booming obesity drug market.
The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year.
The company said it did not observe a plateau in either group of patients, which indicates the potential for further weight loss beyond 52 weeks.
That could boost Amgen's odds of winning a slice of the weight loss drug market, which some analysts forecast could be worth $150 billion a year by the early 2030s.
That's unlike Eli Lilly's obesity drug, Zepbound, which activates both GIP and GLP-1.
Persons:
Amgen, MariTide, Eli Lilly, Robert Bradway, Jay Bradner, Nordisk's Wegovy, Eli Lilly's Zepbound, Zepbound, Eli, Wegovy, Bradner
Organizations:
Novo Nordisk, Nordisk's
Locations:
Amgen, Thousand Oaks , California